New research supports brain cell transplantation as a treatment for some neurological disorders
The transplantation of astrocytes — a type of brain cell as common as neurons — may provide hope of treatments or cures of some neurodegenerative disorders.
Albert HiuKa Fok, Postdoctoral Fellow in Neuroscience, McGill University, Sabrina Chierzi, Research Associate, Neuroscience, McGill University
6 November 2024
Astrocytes — named for their star-like shape — are a type of brain cell as abundant as neurons in the central nervous system, but little is known about their role in brain health and disease.
Many neurological diseases are caused by or result in the loss of cells in the central nervous system. Some diseases are a result of the loss of specific cells, such as the loss of motor neurons in amyotrophic lateral sclerosis (ALS), the loss of dopaminergic neurons in Parkinson’s disease and the loss of GABAergic neurons in Huntington’s disease.
For other neurodegenerative conditions, like Alzheimer’s disease, a key hallmark is the general loss of cells in brain regions responsible for memory formation.
Although many brain diseases are marked by the loss of specific cells, a common link among these diseases is the loss of astrocytes. Interestingly, in some animal studies involving cases such as ALS, introducing disease-causing mutations selectively in astrocytes alone produces ALS symptoms and disease progression.
Transplantation therapy
Emerging evidence indicates that astrocytes take part in major functions of the brain, including homeostasis and neural network modulation that are essential to everyday cognition. A functioning brain requires healthy astrocytes, and finding strategies to heal or replace damaged astrocytes could help in the treatment of neurological diseases.
Cell replacement therapy involves transplanting functional cells in patients. In recent years there have been exciting developments in this area with respect to astrocyte transplantation in animal disease models, with one approach even moving to early clinical trial in ALS patients. While there have been some promising outcomes, treatment success varies from one study to the other.
First, we prepared astrocyte cultures in petri dishes by extracting immature astrocytes from the cerebral cortex of newborn mice and expanding the cell population. To track the development of transplanted astrocytes following their delivery to recipient mice, we used astrocytes from genetically modified mice in which astrocytes glow red, and they are transplanted into the brain of mice where astrocytes glow green.
We found that the transplanted astrocytes could survive for up to one year after transplantation, developing normally and integrating into the recipient brain just like the native astrocytes, with just minor differences.
Astrocytes depend on their capability to sense signals and exchange materials within the brain environment through molecules such as receptors and ion channels located on their cell surface. Transplanted astrocytes displayed comparable numbers of such receptors and channels and possessed similar sizes and complexity when compared to native astrocytes.
Transplanted astrocytes do appear to take some time to catch up to and perfectly match astrocytes in the recipient mice in terms of the production of these receptors and ion channels.
Source, type and location
Intriguingly, we also found that the integration of transplanted astrocytes into the recipient is affected by the age of the mouse, which reflects the maturity of the cellular environment the astrocytes are transplanted into. When astrocytes were transplanted to an infant mouse, they could migrate and spread more extensively in the host brain. However, when astrocytes were transplanted into a young adult mouse, they were confined to the site of transplantation.
Astrocytes in different regions of the brain and the spinal cord display very different features. We were interested in seeing how astrocytes from one region of the brain integrated into a different region. Astrocytes prepared from the cerebral cortex ended up developing into cortical astrocytes even when placed into the cerebellum.
Therefore, the source and type of astrocytes being transplanted makes a difference, and this intrinsic programming of astrocytes needs to be considered when thinking about astrocyte replacement therapy.
Therefore, it presents a promising and exciting strategy to treat neurological diseases. By answering principle questions regarding how transplanted astrocytes integrate in the host, our research can support the development of more effective cell therapies that can improve the quality of life of patients.
Albert HiuKa Fok receives funding from FRQS.
Sabrina Chierzi does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
This article is republished from The Conversation under a Creative Commons license.
RUGBY Ireland centre Garry Ringrose believes the All Blacks' intimidation factor remains, despite having fashioned an impressive record against them over the past eight years More...
BUSINESS Big challenges remain for the labour market More...